(Total Views: 1127)
Posted On: 07/12/2022 10:49:21 AM
Post# of 154133
Quote:
Dostarlimab, a tremendously good PD-1 inhibitor by GSK has shown its effectiveness in treating Colon Cancer, but not metastasis, where LRM executes and excels. Along these lines, PD-1 blockade has been shown to be tremendously effective in treating Long Haulers as has LRM. Dostarlimab and Leronlimab could knock it out of the park.
Why the need for Dostarlimab when leronlimab can handle that?
https://jitc.bmj.com/content/8/1/e000228
(7)
(0)
